Style | Citing Format |
---|---|
MLA | Tabaei S, et al.. "Comparative Proteomics Analysis in Different Stages of Urothelial Bladder Cancer for Identification of Potential Biomarkers: Highlighted Role for Antioxidant Activity." Clinical Proteomics, vol. 20, no. 1, 2023, pp. -. |
APA | Tabaei S, Haghshenas MR, Ariafar A, Gilany K, Stensballe A, Farjadian S, Ghaderi A (2023). Comparative Proteomics Analysis in Different Stages of Urothelial Bladder Cancer for Identification of Potential Biomarkers: Highlighted Role for Antioxidant Activity. Clinical Proteomics, 20(1), -. |
Chicago | Tabaei S, Haghshenas MR, Ariafar A, Gilany K, Stensballe A, Farjadian S, Ghaderi A. "Comparative Proteomics Analysis in Different Stages of Urothelial Bladder Cancer for Identification of Potential Biomarkers: Highlighted Role for Antioxidant Activity." Clinical Proteomics 20, no. 1 (2023): -. |
Harvard | Tabaei S et al. (2023) 'Comparative Proteomics Analysis in Different Stages of Urothelial Bladder Cancer for Identification of Potential Biomarkers: Highlighted Role for Antioxidant Activity', Clinical Proteomics, 20(1), pp. -. |
Vancouver | Tabaei S, Haghshenas MR, Ariafar A, Gilany K, Stensballe A, Farjadian S, et al.. Comparative Proteomics Analysis in Different Stages of Urothelial Bladder Cancer for Identification of Potential Biomarkers: Highlighted Role for Antioxidant Activity. Clinical Proteomics. 2023;20(1):-. |
BibTex | @article{ author = {Tabaei S and Haghshenas MR and Ariafar A and Gilany K and Stensballe A and Farjadian S and Ghaderi A}, title = {Comparative Proteomics Analysis in Different Stages of Urothelial Bladder Cancer for Identification of Potential Biomarkers: Highlighted Role for Antioxidant Activity}, journal = {Clinical Proteomics}, volume = {20}, number = {1}, pages = {-}, year = {2023} } |
RIS | TY - JOUR AU - Tabaei S AU - Haghshenas MR AU - Ariafar A AU - Gilany K AU - Stensballe A AU - Farjadian S AU - Ghaderi A TI - Comparative Proteomics Analysis in Different Stages of Urothelial Bladder Cancer for Identification of Potential Biomarkers: Highlighted Role for Antioxidant Activity JO - Clinical Proteomics VL - 20 IS - 1 SP - EP - PY - 2023 ER - |